Tecarfarin is in clinical development for the prevention of thromboembolism in patients requiring long-term blood thinning treatment. Venous thromboembolism (VTE) refers to a blood clot that develops in a vein. There are two types of VTE: deep vein thrombosis (DVT) which refers to a blood clot in a vein and pulmonary embolism (PE) which refers to a blood clot that has broken free and travelled to the lungs.. Some patients who have had a VTE require long- term treatment with blood-thinning medication to reduce the risk of VTE recurrence.
Tecarfarin, a vitamin K reductase, is given by oral administration and works by blocking the liver from using vitamin K to make clotting factors. Clotting factors work with blood cells called platelets that trigger the clotting process to form a blood clot. Stopping the activation of these vitamin K dependent clotting factors means the blood takes much longer to clot so there is a decreased risk of VTE. Tecarfarin works in the same way as warfarin, which is the current best treatment option for preventing VTE, but is expected to be safer and deliver more predictable clotting. If licensed, tecarfarin would offer an additional treatment option for preventing VTE in patients who require long-term anticoagulation therapy.
Drugs
November 2020
Imetelstat for Myelodysplastic syndrome
Imetelstat is in clinical development for the treatment of relapsed/refractory low or intermediate-1 risk myelodysplastic syndrome (MDS) in transfusion-dependent patients, following erythropoiesis-stimulating agent (ESA) treatment. MDS are a group of disorders in which red blood cells, white blood cells, and platelets produced by the bone marrow do not grow and mature normally. MDS are long-term debilitating and life-threatening diseases. MDS patients may require repeated blood transfusions and currently have few treatment options.